Balsam Health Services, the UAE-based provider of innovative and advanced healthcare solutions focused on early detection and prevention, is stepping up its mission of taking its expertise in cutting edge diagnostic tools – including the revolutionary hPG80 cancer detection test – to wider markets.
As the exclusive Gulf partner of Biodena Care –– the French research and development company that provides therapeutic and diagnostic tools in oncology – and backed by partnerships with leading global medical institutions, Balsam has expanded its portfolio of healthcare solutions with a focus on healthy lifestyle choices and personalised care. The portfolio includes early cancer detection and genetic testing (EPLIMO DNA Test), among others.
Since the UAE has high mortality rate among cancer patients, Balsam Health is advocating the use of the revolutionary hPG80 test, which can detect 16 types of cancers with high accuracy levels of up to 94%. Balsam has tied up with Sharjah University Hospital for collaborative trials for early detection of cancer, as part of this mission.
Abdulkader Awad, CEO of Balsam Health Services, says: “The UAE government has been at the forefront of innovation and technology adoption for diagnosis and treatment of critical health conditions, including cancer. Our work aligns directly with these efforts, and provides residents and healthcare providers across the UAE and the region with access to cutting-edge technology and testing solutions for cancer early detection and prognosis.
“The hPG80 Blood Test is the first of its kind in the world capable of detecting the presence of cancer activity in the body even before initial symptoms appear, empowering oncologists with the crucial advantage of timely intervention, thereby redefining patient outcomes. Our goal is to help increase survival rates of cancer through early detection, which is now possible with the hPG80 test.”
Balsam Health Services, which is showcasing its advanced services at Arab Health exhibition at Dubai World Trade Centre from January 27 to 30, 2025, has positioned itself as a healthcare player deploying innovative technology to provide high-quality customized services enhanced through collaborations with prestigious global medical institutions, bringing advanced diagnostic tools to the GCC region.
Balsam’s key areas of specialisation cover preventive healthcare services (early cancer detection through hPG80); Epigenetic testing to provide personalized health and wellness lifestyle modification (EPLIMO DNA Test); international medical consultation providing access to global expertise; high-quality medical tourism/travel concierge; and discounts on healthcare services from a network of renowned medical institutions.
Balsam has collaborated with leading medical institutions to bring advanced medical diagnostics and expertise to the Gulf. By offering direct access to second medical opinions and international consultations from top specialists in the US, UK, and Europe. This ensures accurate, unbiased diagnosis, and effective treatment planning.
Balsam’s genetic testing services, such as EPLIMO, stand out due to their focus on personalized health plans tailored to an individual’s genetic profile. This ensures clients receive precise recommendations for nutrition, fitness, and preventive care.
